GSK Seeking Up to $2B Bolt-on Acquisitions in India
publication date: Oct 4, 2011
GlaxoSmithKline is looking to complete “smaller” acquisition targets in India in the $500 million to $2 billion range, according to the company’s CEO Andrew Witty. He characterized these transactions as bolt-on additions rather than transformative ones. GSK does not need a large acquisition, he said, because the company already has a well-established presence in India with a recognizable brand name. His comments would seem to apply equally to China, where GSK has been involved in several "smaller" M&A transactions. More details....
Stock Symbol: (NYSE: GSK) Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.